The study shows brain changes occur as early as age 50, up to 15 years before the earliest memory loss symptoms of Alzheimer's occur. TheHealthSite.com
Japan's Eisai said on Monday the country's health ministry had approved its Alzheimer treatment Leqembi, co-developed with U.S.-based Biogen. The drug is the first treatment shown to slow progression of the disease for people in the earlier stages of Alzheimer's. An Eisai executive said in August the company expected to begin marketing Leqembi in Japan within about 60 days of receiving insurance reimbursement approval from the country's national health system.